AbbVie Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? AbbVie Inc trades at $249.8 (market cap $441.94B), while Consumer Staples Select Sector SPDR Fund trades at $84.56. The key difference: AbbVie Inc pays a 2.77% dividend while Consumer Staples Select Sector SPDR Fund pays none, and AbbVie Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ABBV | XLP | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | — |
52-Week High | $263.58 | $90.00 |
52-Week Low | $197.38 | $75.61 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
XLP, the Consumer Staples Select Sector SPDR ETF, trades at $84.585, down 0.43% today. Technical indicators show a neutral overall signal with bullish moving averages, while oscillators remain neutral. The ETF's 2.6% dividend yield provides income appeal, with a dividend scheduled for payment on June 24, 2026. Recent news highlights consumer staples as a defensive play amid market rotation, with Coca-Cola's strong Q2 2026 earnings underscoring sector resilience (ETF Trends, July 29, 2026).
Outlook remains positive given 100% analyst buy ratings and defensive positioning during economic uncertainty. Key risks include sector concentration and sensitivity to consumer spending shifts. The ETF's stability and income generation support a favorable risk-reward profile for conservative investors seeking exposure to essential consumer goods.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →